CYP3A4 and acute myeloid leukemia: Alternatively, as has recently been shown in the German‐Austrian AML Study Group 16–10, dose reductions amidst concurrent strong CYP3A4 inhibitors (Table S3) could also be considered upfront (e.g., 25 mg every other day) without compromising treatment efficacy.30